AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study

Pallavi Madhiraju- June 29, 2023 0

AstraZeneca's IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the ... Read More